MCUJFOTCPharmaceutical PreparationsFiscal year ends December 31

MEDICURE INC

Financials through Q1 FY2025, quarter ended Mar 31, 2025Last filing: 20-F on Apr 24, 2026

$3.10+0.12 (+4.07%)

Close on Oct 19, 2026

Debt

Borrowings on the balance sheet, Mar 31, 2025

Medicure reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Medicure's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Medicure's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Nov 2, 2012
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MCUJF.

Revenue growth1.0% · median -1.1%

Gross margin59.7% · median 78.9%

Company	Revenue	Growth
LXRX	$41.47M	-29.0%
SBFM	$35.35M	-2.7%
CPIX	$31.27M	-1.1%
JAGX	$27.82M	+135.5%
MCUJF	C$21.91M	+1.0%
EVFM	$18.05M	+4.5%

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 22
Auditor: Ernst & Young LLP
SEC CIK: 1133519

Advertisement
300 × 250